The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.02
Bid: 1.82
Ask: 2.19
Change: 0.00 (0.00%)
Spread: 0.37 (20.33%)
Open: 2.02
High: 0.00
Low: 0.00
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Mon, 07th Feb 2022 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alphawave IP Group PLC - designs and licences chip technology - Teams with Intel Corp's Intel Foundry Services. Intel Foundry is a unit of Santa Clara, California-based Intel. It manufactures third-party chips. "By combining Intel's manufacturing and operational prowess with Alphawave IP's technology leadership in connectivity solutions, the partnership will enable some of the world's largest chip companies and hyperscalers to build the most advanced semiconductor devices in 2022 and beyond," Alphawave says.

----------

Cadence Minerals PLC - London-based investor in mineral resources - Says required contractual and regulatory documentation completed and filed at Amapa iron ore project, sealing process and ensuring Cadence now owns 20% of the Brazil-based project. Cadence notes Anglo American PLC, a previous owner, valued the asset at USD1.2 billion and impaired it at USD600 million back in its 2012 accounts.

----------

Oilex Ltd - Perth-based company focused on the development of natural gas assets - India's Ministry of Environment, Forest & Climate Change confirms decision to approve environmental clearance for Cambay field.

----------

Hunting PLC - London-based supplier to oil and gas industry - Refinances core borrowing facilities and enters into USD150 million asset based lending facility with Wells Fargo and HSBC. New facility has four-year term and replaces USD160 million revolving credit facility. "The ABL facility contains an accordion feature of up to a further USD50 million which is accessible subject to further credit approval from the relevant lenders, enabling the company to increase the total facility quantum to USD200 million," Hunting adds.

----------

Helium One Global Ltd - London-based exploration & development company - Begins electrical resistivity tomography at Rukwa asset. Survey will probe area identified from phase I and phase II 2D seismic surveys. Will also investigate "surface helium anomalies identified in recently completed multispectral satellite spectroscopy study".

----------

Wildcat Petroleum PLC - targeting investment opportunities in businesses and assets within the upstream sector of the petroleum industry, including the use of blockchain within the sector - Names PETRO-TEC as petroleum consultants. "PT will be able to devise, implement, run and evaluate appropriate field development projects alongside WCAT," company says.

----------

Insig AI PLC - London-based machine learning and data science firm which serves the asset management industry, formerly known as Catena Group PLC - Picked for PwC's Scale FinTech programme, aiming to give access to new opportunities within the accounting firm and its clients. "After an extensive selection process, Insig AI was one of only nine companies this year chosen from more than 700 applicants from around the world. Insig AI is also the only FinTech with ESG expertise on the programme," Insig says.

----------

Octopus Renewables Infrastructure Trust PLC - London-based investment company focused on renewable energy assets in Europe and Australia - Declares 1.25 pence per share dividend for fourth quarter ended December 31. Notes 2021 payout totals 5.0p per share, meeting target. For 2022, it eyes 5.24p payout, up 4.8%.

----------

ImmuPharma PLC - London-based drug discovery and development company - Says UK Medical & Health Products Regulatory Agency approves pharmacokinetic study Lupuzor in Lupus patients. "Volunteers have been selected and approved for inclusion in the PK study," company says. Vounteer dosing to begin on February 15 and study on track to deliver results by end of first quarter.

----------

Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Treats first patients in phase 2 of US Food & Drug Administration nasal photodisinfection exploratory trial. "The study will evaluate how effectively the treatment eradicates pathogens -Staphylococcus aureus - in the nose, and the occurrence of surgical site infections within 30 days of surgery," Ondine adds.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Dec 2019 12:12

ImmuPharma To List On Life Sciences Heavy Brussels Index

ImmuPharma To List On Life Sciences Heavy Brussels Index

Read more
11 Dec 2019 14:54

ImmuPharma says not looking to raise funds

(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.

Read more
11 Dec 2019 14:03

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

Read more
28 Nov 2019 16:26

ImmuPharma shares soar as it teams up with Avion on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.

Read more
28 Nov 2019 12:02

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Read more
28 Nov 2019 07:28

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....

Read more
30 Sep 2019 10:40

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

Read more
28 Jun 2019 12:01

Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor

(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug

Read more
28 Jun 2019 10:27

ImmuPharma pleased with Lupuzor open-label study results

(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.

Read more
26 Jun 2019 11:15

Immupharma raises ?2.66m from subscription agreement with institutional investor

(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.

Read more
26 Jun 2019 10:14

Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead

(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development

Read more
24 May 2019 11:47

Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline

LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a

Read more
7 May 2019 11:06

ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)

LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a

Read more
1 Apr 2019 14:07

ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a

Read more
14 Mar 2019 11:04

ImmuPharma struggles to convince investors in latest update

(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.